Tokyo, Japan

Hitoshi Iimori

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hitoshi Iimori: Innovator in Pharmaceutical Chemistry

Introduction

Hitoshi Iimori is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have the potential to inhibit the production or secretion of β-amyloid protein, which is associated with neurodegenerative diseases.

Latest Patents

Iimori holds a patent for a compound known as a heterocyclic methyl sulfone derivative. This compound is represented by a specific formula and is capable of inhibiting the production or secretion of β-amyloid protein. The patent details various structural components of the compound, including heterocyclic groups and cyclic hydrocarbon groups, which may have substituents. Additionally, the patent covers N-oxides, S-oxides, salts, and solvates of the compound, as well as medicaments containing any of these forms.

Career Highlights

Hitoshi Iimori is associated with Daiichi Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development in pharmaceutical innovations. His work focuses on creating effective therapeutic agents that can address critical health issues.

Collaborations

Iimori has collaborated with notable colleagues, including Hideki Kubota and Takanori Yasukouchi. These collaborations have contributed to the advancement of research in the pharmaceutical field.

Conclusion

Hitoshi Iimori's innovative work in developing compounds to inhibit β-amyloid protein production highlights his significant role in pharmaceutical chemistry. His contributions continue to impact the field and offer hope for future therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…